NanoViricides, Inc. entered into a master services agreement with regulatory consulting firm Only Orphans Cote, LLC to secure orphan drug designation for its broad‑spectrum antiviral candidate NV‑387. The partnership focuses on indications that qualify as orphan diseases, including smallpox, mpox, and measles, and will provide the company with specialized expertise to navigate the U.S. Food and Drug Administration’s Office of Orphan Products Development process.
The agreement is expected to unlock a suite of incentives for NV‑387, including tax credits for clinical trials, fee waivers, and a seven‑year period of market exclusivity upon approval. These benefits could accelerate the drug’s development timeline and enhance its commercial prospects by reducing upfront costs and protecting the company’s investment in a highly competitive antiviral market.
Only Orphans Cote, founded by former FDA official Dr. Timothy Cote, brings deep experience in orphan drug applications. Dr. Cote’s track record—over 1,400 applications reviewed and more than 200 orphan drugs approved—positions the consultancy to streamline the designation process and mitigate regulatory risks that often delay or derail similar programs.
NanoViricides’ leadership highlighted the strategic fit of the partnership. President and Executive Chairman Anil R. Diwan noted that pursuing orphan status for NV‑387 aligns with the company’s broader pipeline strategy, which targets rare and high‑impact viral diseases that lack effective treatments. The move also signals confidence in NV‑387’s broad‑spectrum activity, demonstrated in animal models against orthopoxviruses, measles, RSV, COVID‑19, and influenza.
While the agreement’s financial terms were not disclosed, the collaboration underscores NanoViricides’ commitment to leveraging external expertise to accelerate regulatory milestones. By securing orphan designation, the company could reduce development costs and secure a competitive advantage in a market where few broad‑spectrum antivirals exist.
The partnership reflects a broader industry trend of biopharmaceuticals seeking orphan status to offset high development costs and secure market exclusivity, especially for drugs targeting rare or emerging infectious diseases. For NanoViricides, the agreement represents a critical step toward translating preclinical success into a viable commercial product that could serve both pandemic preparedness and niche therapeutic needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.